Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects With Relapsed/Recurrent Glioblastoma Multiforme (GBM)

NCT02765165 is registered in ClinicalTrials.gov with Proximagen, LLC as lead sponsor.

NCT NCT02765165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02765165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects With Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Lead sponsor
Proximagen, LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2016
Completion date
July 1, 2020
Enrollment
26 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/recurrent gbm (phase 2), solid tumors (phase 1)